Loxo Oncology, Inc. (LOXO) [Rocket]

Overview

Loxo Oncology, Inc. (LOXO)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
02/14/2020	SC 13G/A	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/08/2020	SC 13G/A	WELLINGTON MANAGEMENT GROUP LLP reports a 0% stake in Loxo Oncology, Inc.
02/25/2019	15-12B	Form 15-12B - Securities registration termination [Section 12(b)]:
02/22/2019	EFFECT	Form EFFECT - Notice of Effectiveness:
02/15/2019	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
02/15/2019	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
02/15/2019	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14	Dec-31-13
Revenues	21.3	0.0	0.0	0.0	0.0
Cost of goods sold	0.0	0.0	0.0	0.0	0.0
Gross profit	21.3	0.0	0.0	0.0	0.0
Gross margin	100.0%
Selling, general and administrative					0.0
Research and development	140.0	58.3	14.0	6.9
General and administrative	33.7	14.9	10.5	6.2	0.0
EBITA	-152.3	-72.7	-35.7	-20.7	0.0
EBITA margin	-715.1%
Amortization of intangibles	0.1	0.5	0.4	0.0
EBIT	-152.4	-73.2	-36.1	-20.7	0.0
EBIT margin	-715.5%
Pre-tax income	-148.9	-72.4	-35.9	-20.7	0.0
Income taxes	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.1%
Net income	-148.9	-72.4	-35.9	-20.7	0.0
Net margin	-698.9%

Diluted EPS	($5.31)	($3.46)	($2.12)	($3.06)
Shares outstanding (diluted)	28.0	20.9	16.9	6.8

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.